Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
183 studies found for:    immunization [CONDITION] AND child [AGE-GROUP] | Open Studies
Show Display Options
Rank Status Study
21 Unknown  Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.
Condition: Measles Vaccine
Intervention: Biological: Early measles vaccine
22 Unknown  Trial of Additional Measles Vaccine to Reduce Child Mortality
Condition: Measles Vaccine
Intervention: Biological: Early measles vaccine
23 Recruiting Strengthening Physician Communication About HPV Vaccines
Condition: HPV Immunization Status
Intervention: Behavioral: Multimodal Vaccine Program
24 Not yet recruiting Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old
Condition: Enterovirus 71 Vaccine
Intervention: Biological: two doses enterovirus 71 vaccine
25 Recruiting Evaluate Safety of ComBe Five (Liquid) in Healthy Vietnamese Children Aged From 8 - 10 Weeks as a 3-dose Series, Interval for Each Dose is 4 Weeks
Condition: Safety, Pentavalent Vaccine
Intervention: Biological: ComBe Five (Liquid)
26 Unknown  Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea
Conditions: Gastroenteritis;   Rotavirus Vaccines;   Cost-Effectiveness
Intervention:
27 Recruiting Speed of Injection and Pain During Routine Infant Vaccinations
Conditions: Routine Infant Immunizations;   Pain Management
Interventions: Other: Fast injection speed by immunizer;   Other: Slow injection speed by immunizer
28 Recruiting Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)
Conditions: Yellow Fever Vaccine;   Immunity
Intervention: Biological: yellow fever vaccine
29 Recruiting Immunogenicity and Safety of Gardasil-9 and Cervarix
Condition: HPV Vaccines Immunogenicity and Safety
Interventions: Biological: Gardasil-9 and Gardasil-9;   Biological: Cervarix and Gardasil-9
30 Unknown  Influenza Vaccination in Patients With Scleroderma
Condition: Influenza Vaccine in Scleroderma
Intervention: Biological: Influenza vaccine
31 Unknown  FluMist in Egg Allergic Patients
Conditions: Egg Allergy;   Eligible for Vaccination Against Influenza
Interventions: Biological: FluMist intranasal influenza vaccine;   Biological: Intramuscular influenza injection ("flu shot")
32 Unknown  Facilitating Completion of HPV Vaccination
Condition: Adolescent Immunizations Among Clinic Population
Intervention:
33 Not yet recruiting A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix® -IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
Conditions: Haemophilus Influenzae Type B Vaccines;   Diphtheria;   Hepatitis B;   Tetanus;   Pertussis
Intervention: Biological: Infanrix® -IPV/Hib
34 Not yet recruiting A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children
Condition: Adverse Event Following Immunisation
Intervention: Biological: SABIN monovalent OPV2
35 Unknown  Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients
Conditions: Serology Analysis;   Novel H1N1 Influenza Vaccination;   Pediatric Haemato-oncology Patients
Intervention: Biological: Influenza A (H1N1) 2009 monovalent vaccine, inactivated
36 Not yet recruiting Synchronized Immunization NotifiCations
Condition: Vaccination
Intervention: Behavioral: Electronic immunization alert
37 Unknown  Automated SMS Reminders to Parents on Their Cell Phones Can Significantly Improve the on Time Vaccination Rates Children in Pakistan
Condition: Vaccination Failure
Intervention: Behavioral: SMS reminders
38 Unknown  SMS Reminders to Improve the on Time Vaccination Rates Among Children in Pakistan
Condition: Vaccination Failure
Intervention: Behavioral: Short message service
39 Recruiting Assessment of Community Transmission of Sabin Type 2 Virus in Bangladesh
Condition: Vaccine Virus Shedding
Interventions: Biological: tOPV;   Biological: bOPV;   Biological: IPV
40 Not yet recruiting Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
Condition: Malaria Vaccines
Interventions: Dietary Supplement: Vitamin A;   Biological: Candidate Plasmodium falciparum malaria vaccine;   Biological: MR-Vac;   Biological: Stamaril

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years